Demographics | | | |
Sex | | | |
Male | 89 (51) | | |
Female | 84 (49) | | |
Race/ethnicity | | | |
White | 124 (72) | | |
Asian | 3 (2) | | |
Black | 21 (12) | | |
Hispanic | 18 (10) | | |
Others | 7 (4) | | |
Current age (yr) | | 14.4 (4.6) | 13.5 (10.7–17.6) |
Patient's highest education (yr) | | 7.7 (3.9) | 7.0 (4.0–11.0) |
Maternal education (yr) | | 13.6 (2.5) | 13.0 (12.0–16.0) |
Paternal education (yr) | | 13.6 (3.1) | 12.0 (12.0–16.0) |
Treatment characteristics | | | |
Age at diagnosis (yr) | | 6.7 (4.3) | 5.3 (3.5–8.6) |
Time since diagnosis (yr) | | 7.7 (1.8) | 7.5 (6.3–9.1) |
Treatment risk stratum | | | |
Low | 102 (59) | | |
Standard | 71 (41) | | |
Chemotherapy dosesa | | | |
Oral dexamethasone (mg/m2) | | 1096.4 (303.2) | 1099.9 (985.3–1246.1) |
IV high-dose cytarabine (g/m2) | | 8.5 (3.5) | 8.0 (8.0–8.0) |
IV leucovorin (mg/m2) | | 343.5 (207.1) | 300.0 (220.0–390.0) |
IV high-dose methotrexateb (g/m2) | | 15.4 (6.7) | 14.2 (11.4–19.0) |
IT MHA (No. of counts) | | 14.4 (4.0) | 13.0 (12.0–16.0) |